http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfenex to Participate at Two Investor Conferences in March
-
Pfenex to Host Conference Call and Webcast Reporting Fourth Quarter Financial Results on Monday, March 11th
-
Pfenex (PFNX) Announces FDA Acceptance of NDA for PF708
-
Pfenex Announces FDA Acceptance of NDA for PF708
-
Pfenex (PFNX) Submits NDA to U.S. FDA Seeking Approval of PF708 for Treatment of Osteoporosis
-
Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis
-
Pfenex Reports Third Quarter Results and Provides Business Update
-
Pfenex to Host Conference Call and Webcast Reporting Third Quarter Financial Results on Wednesday, November 7
-
Pfenex Reports New Employment Inducement Award Under NYSE American Listing Rules
-
Pfenex to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
-
Pfenex Names Dr. Shawn A. Scranton as Sr. Vice President and Chief Operating Officer
-
Pfenex to Present at the Liolios 7th Annual Gateway Conference
-
Pfenex Announces Departure of Chief Medical and Scientific Officer Dr. Hubert Chen
-
Pfenex Reports Second Quarter Results and Provides Business Update
-
Liolios 7th Annual Gateway Conference to Showcase 100 Leading Companies at the Four Seasons San Francisco September 5-6, 2018
-
Pfenex to Host Conference Call and Webcast Reporting Second Quarter Financial Results on Wednesday, August 8
-
Pfenex (PFNX) Secures Milestone Payment from Merck (MRK) for Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
-
Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
-
Pfenex Set to Join Russell 2000® Index
-
Pfenex to Present at the JMP Securities 2018 Life Science Conference
-
Pre-Open Movers 06/12: (GLMD) (RH) (PLAY) Higher; (IDRA) (JCAP) (IMMU) Lower (more...)
-
Pfenex (PFNX), Alvogen Enter U.S. Agreement for Commercialization of PF708
-
Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a Therapeutic Equivalent Candidate to Forteo®
-
Pfenex to Present at the Jefferies 2018 Global Healthcare Conference
-
Pfenex (PFNX) Reports Positive Top-Line PF708 Study Results in Osteoporosis Patients; On-Track for Submission of NDA in Q3
-
Pfenex Announces Positive Top-Line PF708 Study Results in Osteoporosis Patients, On-Track for Submission of New Drug Application in Third Quarter 2018
-
Pfenex Reports First Quarter 2018 Results and Provides Business Update
-
Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th
-
Pfenex (PFNX) Reports Development & License Agreement with NT Pharma Group for PF708 Therapeutic Equivalent Candidate to Forteo
-
Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo®
-
Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update
-
Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference
-
Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018
-
Pfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference
-
Pfenex (PFNX) Appoints Susan Knudson as CFO
-
Pfenex Names Susan A. Knudson as Chief Financial Officer
-
Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals
-
Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference
-
Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update
-
Pfenex to Report Third Quarter 2017 Results and Provide Business Update on Thursday, November 9, 2017
-
Pfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017
-
Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules
-
Pfenex To Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017
-
Pfenex To Present at the 6th Annual Liolios Gateway Conference on September 6th, 2017
-
Pfenex Reports Second Quarter 2017 Results and Provides Business Update
-
Pfenex (PFNX) Names Eef Schimmelpennink as CEO
-
Pfenex Names Eef Schimmelpennink Chief Executive Officer
-
Pfenex To Report Second Quarter 2017 Results and Provide Business Update on Wednesday, August 9, 2017
-
Pfenex Reports First Quarter 2017 Results and Provides Business Update
-
Pfenex To Report First Quarter 2017 Results and Provide Business Update on Monday, May 8, 2017

